Call for Expressions of Interest: Dengue Vaccine

**Invitation to manufacturers of dengue vaccine to submit an expression of interest for financial support to improve availability of dengue vaccine in low- and middle-income countries (LMICs).**

|  |  |
| --- | --- |
| **Release Date** | **29th September 2025** |
| **Closing Date** | **10th November 2025** |
| **Reference**  | **MGL CEI 2025 – Dengue vaccine** |
| **Submission**  | submissions@medaccess.org |

**DISCLAIMER**

This call for expressions of interest (CEI) is issued by MedAccess for planning purposes in respect of its market shaping activities only. MedAccess shall not be under any obligation to purchase or procure any of the services or products or provide any financial tools or volume guarantee (“VG”) to a respondent and the issuing of this CEI shall not be deemed to be a commitment by MedAccess to enter into business relations.

Any information submitted in response to this CEI is provided to MedAccess on a voluntary basis. MedAccess will use the information with a view to assess suitability of a VG or another innovative financial tool, subject to the confidentiality undertakings set out in Section D of this CEI.

All respondents are solely responsible for their costs and expenses incurred in connection with the CEI including the preparation and submission of responses and participation in all future stages (if any) of this process. Under no circumstances will MedAccess be liable for any costs or expenses borne by a respondent, its group companies, any of its supply chain, partners or advisors in this process.

# Introduction

MedAccess is seeking to partner with manufacturers of approved dengue vaccines to improve the availability and affordability of vaccines in low- and middle-income countries.

MedAccess Guarantee Ltd (“MedAccess”) is a social finance company established with the intention of making medical supplies more widely available at lower prices in underserved markets, specifically through the provision of financial tools including loans and guarantees to pharmaceutical and medical device suppliers. Established in November 2017, MedAccess is a wholly-owned subsidiary of British International Investment (“BII”), the UK’s development finance institution and wholly-owned by the UK Government.

MedAccess provides market shaping tools such as volume guarantees to reduce business risks and address inefficiencies in access to medical supplies. A VG is an agreement made with the objective of ensuring stable, affordable supply and catalysing demand. Under a VG, the supplier or manufacturer commits to sell at a mutually agreed ceiling price. If annual sales are less than an agreed target, MedAccess will make a shortfall payment to the supplier or manufacturer at an agreed price per unit subject to the terms and conditions of a VG. MedAccess has executed 12 transactions to date supporting access to HIV, TB, malaria and COVID-19 commodities.

# Purpose and eligibility

Dengue is one of the most widespread vector-borne diseases in the world, with over 100 million symptomatic cases annually across Asia, Latin America and parts of Africa. Severe dengue can be life-threatening, placing a heavy burden on health systems and economies in endemic countries.

The global incidence of dengue increased ten-fold between 2000 and 2019 and is projected to continue rising, driven by urbanisation, climate change and population mobility.

In recognition of its escalating impact, the World Health Organization (WHO) declared a grade 3 global dengue emergency in December 2023, calling for a coordinated international response incorporating strengthened surveillance, resource mobilisation and enhanced vector control measures.

Despite recent advances in dengue vaccine development, access in low- and middle-income countries (“LMICs”) remains constrained due to:

* **Uncertain demand forecasts**, making it difficult for manufacturers to plan production efficiently.
* **High vaccine prices** compared to routine immunisation budgets.
* **Limited early financing commitments**, slowing national uptake and introduction.

Dengue vaccine suppliers face unpredictable demand and limited market insight in donor-funded countries and LMICs, making capacity planning and pricing decisions difficult.

To accelerate access, MedAccess is exploring whether financial tools, including volume guarantees, could be used to support dengue vaccine manufacturers to lower prices, expand production and catalyse uptake in LMICs. The purpose of this CEI is to invite manufacturers to submit information (using the form in the Appendix) outlining:

* The product profile and regulatory pathway for their dengue vaccine.
* The price: volume matrix that could be achieved with increasing sales volumes.
* The type of external support (financial tools, implementation partnerships, market-shaping activities) that could unlock greater affordability and uptake.

This detail will help to determine the product price that could be offered across the target LMICs: if 1) high annual sales volumes are achieved and 2) a guarantee and implementation support is made available.

This CEI applies to manufacturers of dengue vaccines that:

1. Have already obtained or plan to submit for WHO Prequalification or other stringent regulatory approval between now and 2030.
2. Can supply formulations appropriate for use in endemic LMIC settings.

# Respondent Representations

By submitting a response to this CEI, the respondent represents to MedAccess that (a) all information provided in the response is accurate, true and correct as of the date of submission and (b) the respondent possesses all necessary rights and authority to submit the information contained within their response.

# Submission instructions

All expressions of interests (“EOIs”) must be submitted in English using the form provided in the Appendix and be signed (electronically or otherwise) by the authorised representative of the respondent. Interested respondents should fully complete and return the Appendix form electronically to submissions@medaccess.org by 10th November 2025 with ‘MGL CEI [year]\_deal name – Expression of Interest: [name of the company]’ in the email subject line.

MedAccess may request additional information to supplement or verify the information provided in the EOI, arrange interviews with the respondent and/or visit the respondent’s premises and facilities, if it deems necessary.

The receipt timestamp is the date and time the submission has been received, as indicated by the log files of the email received. It is the sole responsibility of manufacturer to ensure that the EOI and related documents are received on or before any prescribed deadline.

# Confidentiality

Information provided by the respondent will be received by MedAccess. In the event that MedAccess engages partners or service providers (“Partners”), such information may be disclosed to such Partners on a need-to-know basis and solely for the purpose of fulfilling the objectives of the Purpose. All information will be used by MedAccess for assessment purposes. Any information submitted in the EOI that needs to be treated as “confidential” should be clearly marked as such on the completed form by the respondent. Where MedAccess and the respondent have a non-disclosure agreement (“NDA”) in place, information marked confidential will be treated as Confidential Information in accordance with the terms of such NDA. Otherwise, when information is marked confidential, MedAccess will take all reasonable measures to keep the information confidential and will not share it with other entities or individuals outside MedAccess and its advisors without the respondent’s written authorization. This confidentiality commitment shall not apply if the information concerned, or any part of it: (a) was known to MedAccess prior to any disclosure by the respondent; or (b) was in the public domain at the time of disclosure by the respondent; or (c) becomes part of the public domain through no fault of MedAccess; or (d) becomes available to MedAccess from a third party who is not in breach of any legal obligation of confidentiality to the respondent. If processing the EOI involves the recording and processing of personal data (such as name, address), such data will be processed pursuant to MedAccess’ privacy policy, which is available at <https://medaccess.org/privacy-policy/> . Information relating to the examination, clarification, and evaluation of EOI shall not be disclosed to other respondents or any other persons not officially concerned with such process.

# Process and Timelines

All EOIs must be submitted in English and be signed (electronically or otherwise) by the authorised representative of the manufacturer.

Interested manufacturers should complete and return the **EOI Manufacturer Response Form** (see Appendix) electronically to **submissions@medaccess.org** by 10th November 2025 with ‘MGL CEI [year]\_deal name – Expression of Interest: [name of the company]’ in the email subject line.

MedAccess may request additional information to supplement or verify the EOI, arrange interviews with the manufacturer, and/or visit facilities if deemed necessary. All EOIs will be reviewed, and decisions communicated by 24th November 2025.

MedAccess reserves the right to amend the timetable at any time during the process and to end the process at its sole discretion.

Any information provided by MedAccess is provided on a reasonable endeavours basis, MedAccess provides no warranty as to the accuracy of the information and the respondent should carry out its own due diligence in respect of any matters relating to the process or the opportunity.

# Contact Information

Any questions about the CEI process or MedAccess should be submitted to:

Panayota Bird

PBird@MedAccess.org

# Appendix: EOI: Manufacturer Response

1. **Company and Product Information**
* Complete the table below and attach **product specifications** to the submission.

|  |
| --- |
| **Corporate information** |
| **Company name** | *[Company name]* |
| **Contact point**  | *[Name, title, email address, contact number]* |
| **Company headquarters**  | *[Address]* |
| **Manufacturing location** | *[Site Name, Address]* |
| **Product overview**  | *[Product name and code (where applicable), Presentation (e.g., Multidose Vial, Prefilled Syringe), Vial Size and Pack Dimensions, Storage Requirements]* |
| **List of Countries** | *[List of existing markets where this product is sold, if applicable]* |
| **Total shelf-life**  | *[In months, for* *Drug Substance, Drug Product, Filled and Finished product]* |
| **Typical shelf-life at delivery** | *[In months]* |
| **Antigen Source & Supplier** | *[Origin and identity of the antigen used in the vaccine, including details of the contracted or in-house supplier]* |
| **Production capacity** | *[Production capacity allocated/ anticipated per year for this product]* |
| **Storage conditions** | *[Including temperature requirements]* |
| **Performance Data** | *[Evidence on safety, efficacy, immunogenicity, and cost-effectiveness derived from clinical or real-world studies]* |
| **Ongoing studies/ Plans for Additional Studies** | *[Current or planned clinical trials, post-marketing studies, or operational research to generate further evidence]* |
| **Year of Market Entry** | *[Anticipated launch year for commercial availability in target markets]* |
| **Target Markets** | *[Intended countries or regions of introduction, with a focus on LMICs]* |
| **Procurement Channels** | *[Anticipated procurement Channels for Target Markets]* |
| **Quality approvals**  | *[List quality standards followed]* |
| **Compendial compliance** | *[List product compliance]* |

1. **Price: Volume Matrix for Product**

**Price: volume matrix:**

* Use the table below to indicate the anticipated pricing plan with and without a VG.

|  |  |
| --- | --- |
| **Target LMICs** |  |
| **Annual sales**  | **Ceiling price without a VG and other support indicated below**(EXW inclusive of labelling and packaging for target LMICs) | **Ceiling price with a VG and other support indicated below**(EXW inclusive of labelling and packaging for target LMICs) |
| 500,000- 1M | **-** | **-** |
| 1M-2M | **-** | **-** |
| 2M-3M | **-** | **-** |
| >3M | **-** | **-** |

**Required support to improve/ stabilise pricing:**

|  |
| --- |
| *Please describe the challenges of supplying Product in LMICs.* *Please list any product modifications or formulations required for LMIC suitability.**Please describe constraints to achieving higher volumes.**Please also describe which set of support tools[[1]](#footnote-2), particularly volume guarantees, implementation support etc., you would require to improve the pricing indicated in the price: volume matrix.**Please provide details on the required parameters for each tool, e.g. size and duration of volume guarantee. Please also provide details on its benefits and associated impact on your plans.* |

1. **Additional Comments**

|  |
| --- |
| *Any further commentary, e.g. interest in and motivation for working with MedAccess, experience implementing similar partnerships and/ or expected timeline, any other information you consider relevant to enabling wider and more equitable access in LMICs.**If none please confirm "None".* |

1. For more information on MedAccess’ support tools please visit <https://medaccess.org/innovative-finance/our-innovative-finance-products/> [↑](#footnote-ref-2)